The Global Ciclesonide Market, by Indication (Asthma and Allergic Rhinitis), by Dosage Form (Aerosol and Nasal Spray), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 565.4 million in 2018, and is projected to exhibit a CAGR of 1.9% over the forecast period (2018 – 2026).
Inhaled corticosteroids (ICS) such as ciclesonide are at the cornerstone of treatment in asthma and in chronic obstructive pulmonary disease (COPD). The majority of the asthma patients, are treated with a combination of ICS and short- or long- acting bronchodilators. High efficiency of inhaled corticosteroids in treating asthma and COPD incidences is supporting adoption of ciclesonide in the future. For instance, according to the study findings published in the BMJ Journal, in November 2018, use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA), and inhaled corticosteroid (ICS); resulted in lower rate of moderate or severe exacerbations of COPD, better lung function, and better health related quality of life than dual therapy or monotherapy in patients with advanced COPD.
Browse 26 Market Data Tables and 24 Figures spread through 126 Pages and in-depth TOC on ‘Ciclesonide Market, by Indication (Asthma and Allergic Rhinitis), by Dosage Form (Aerosol and Nasal Spray), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026’
To know the latest trends and insights prevalent in the ciclesonide market, click the link below:
Launches and approvals of new ciclesonide products in key regions is expected to create a conducive environment for growth of the ciclesonide market over the forecast period. For instance, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol for the treatment of allergic rhinitis and launched it in the U.S. market. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE). Key players in the market are involved in strategic mergers and acquisition strategies to enter the lucrative market of ciclesonide and to widen its portfolio with various ciclesonide products. Such strategic mergers and acquisitions are expected to support growth of ciclesonide market over the forecast period. For instance, in 2015, a U.K. based AstraZeneca Plc. acquired Takeda Pharmaceutical Company Ltd.’s lung business and widen its offerings with Alvesco, Omnaris ciclesonide. In 2017, Sunovion Pharmaceuticals Inc. (Sunovion) divested its U.S. market rights of Sunovion’s ciclesonide products: ALVESCO (ciclesonide) Inhalation Aerosol, OMNARIS (ciclesonide) Nasal Spray, and ZETONNA (ciclesonide) Nasal Aerosol to Covis Pharma B.V. (Covis Pharma).
Key Takeaways of the Ciclesonide Market: